HiFiBiO Therapeutics Entered into a Clinical Trial Supply Agreement with Novartis to Evaluate HFB200603 + Tislelizumab for DIS Selected Advanced Solid Tumors
Shots:
- The companies collaborated to evaluate HiFiBiO’s HFB200603 (anti-BLTA mAb) + Novartis’ tislelizumab (anti-PD-1 immune checkpoint inhibitor) for the treatment of patients with advanced solid tumor indications
- HiFiBiO Therapeutics will be responsible for maintaining control of the HFB200603 program, incl. R&D and commercial rights globally while Novartis will supply tislelizumab for use in combination with HFB200603 (preselected by DIS platform)
- Through the activation of Ab-dependent macrophage-mediated killing of T effector cells, it has been demonstrated in pre-clinical studies that binding to Fc receptors on macrophages reduces the anti-tumor activity of PD-1 Abs
Ref: HiFiBiO | Image: Novartis
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
